Article Text

Download PDFPDF

742 A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors
  1. Bradley Mcgregor1,
  2. Toni Choueiri1,
  3. Neil Shah2,
  4. Aung Bajaj3,
  5. Jad Chahoud4,
  6. Bert O’Neil5,
  7. Joel Michalski6,
  8. Benjamin Garmezy7,
  9. Lixian Jin8,
  10. Usman Aziz9,
  11. Fiona Xu9 and
  12. Robert Motzer2
  1. 1Dana-Farber Cancer Institute, Boston, MA, USA
  2. 2Memorial Sloan Kettering Cancer Center, New York, NY, USA
  3. 3Arizona Oncology, Tucson, AZ, USA
  4. 4Moffitt Cancer Center, Tampa, FL, USA
  5. 5Indiana University, Indianapolis, IN, USA
  6. 6Nebraska Cancer Specialists, Omaha, NE, USA
  7. 7Sarah Cannon Research Institute, Nashville, TN, USA
  8. 8Bristol Myers Squibb, Lawrenceville, NY, USA
  9. 9Exelixis, Inc., Alameda, CA, USA


Background XL092 is a novel, oral inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL, and MER, which are implicated in tumor growth, metastasis, angiogenesis, and immune modulation. XL092 has a half-life of ~21h, convenient for daily dosing and managing tolerability. Preclinical studies of XL092 plus an immune checkpoint inhibitor (ICI) showed antitumor activity in tumor models. STELLAR-002 will evaluate the safety and clinical activity of XL092 alone and in combination with nivolumab ± ipilimumab in patients with advanced solid tumors. Presented here is the study design which includes a dose-escalation stage in solid tumors and a cohort-expansion stage in genitourinary cancers.

Methods This multicenter phase 1b, open-label study (NCT05176483) will enroll patients with unresectable advanced or metastatic solid tumors. The dose-escalation stage will determine recommended doses of XL092 (orally) in combination with nivolumab ± ipilimumab (intravenously) for the cohort-expansion stage. Dose escalation will enroll a total of ~24 patients into two cohorts using a rolling 6 design: Cohort A, XL092 + nivolumab (360 mg Q3W); Cohort B, XL092 + nivolumab (3 mg/kg Q3W × 4, then 480 mg Q4W) + ipilimumab (1 mg/kg Q3W × 4). The cohort-expansion stage will include six tumor-specific cohorts: clear cell renal cell carcinoma (ccRCC), first-line therapy; ccRCC, second-line therapy after one prior ICI regimen; metastatic castration-resistant prostate cancer (mCRPC), second-line therapy after one prior novel hormonal therapy; urothelial carcinoma (UC), second-line therapy after prior platinum-based regimen and ICI-naïve; UC, ICI-experienced, up to 2 prior lines of systemic therapy with prior platinum-based regimens allowed; non-clear cell RCC, first-line therapy. Cohort-specific randomization will include XL092 alone or in combination with nivolumab ± ipilimumab to evaluate the contribution of the individual agents to the combination regimens. Thirty patients will be enrolled in each XL092 alone arm and 40 patients in each combination arm. Preliminary efficacy, safety, and pharmacokinetics of XL092 alone or in combination with ICI will be assessed in each cohort. Primary endpoints include objective response rate per RECIST v1.1 by investigator, progression-free survival per Prostate Working Group 3 criteria by blinded review (mCRPC cohort only), and safety. The study is enrolling patients.

Trial Registration Trial registry is NCT05176483

Ethics Approval The study will adhere to the principles outlined in ”Guideline for Good Clinical Practice” (GCP) and remain consistent with the most recent version of the Declaration of Helsinki.

Consent Patients will be required to provide written informed consent.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.